Back to top
more

Lisata Therapeutics, Inc. (LSTA)

(Delayed Data from NSDQ)

$2.85 USD

2.85
3,642

+0.01 (0.20%)

Updated May 16, 2024 11:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma

The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises.

Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma

Lisata's (LSTA) lead investigational product candidate, LSTA1, gets Rare Pediatric Disease Designation for treating osteosarcoma. Stock rises.

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

Lisata (LSTA) is progressing well with the development of its lead investigational product candidate, LSTA1, which targets several cancer indications.

All You Need to Know About Lisata Therapeutics, Inc. (LSTA) Rating Upgrade to Buy

Lisata Therapeutics, Inc. (LSTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up

Lisata (LSTA) shares rise 6.6% after its lead candidate, LSTA1, receives orphan drug designation from the European Commission for treating pancreatic cancer.

Lisata (LSTA) Up on Positive Updates for Pancreatic Cancer Study

Lisata's (LSTA) shares gain on a favorable outcome in interim futility analysis of its lead candidate, LSTA1, for pancreatic cancer.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: NVIDIA, VirTra, Rockwell Medical in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: NVIDIA, Lisata, Shopify in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Moderna (MRNA) Posts Upbeat Data on Protein Replacement Therapy

Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.

Perrigo (PRGO) Tops Q1 Earnings & Sales, Reiterates '23 View

Perrigo (PRGO) reports encouraging first-quarter 2023 results. Management reaffirms the financial guidance for 2023. The company's current CEO announces plans to retire by the end of July.

Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q1

Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.

Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.

Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%

Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine

Allogene's (ALLO) Q1 Loss Wider Than Expected, Sales Miss

Allogene's (ALLO) first-quarter results miss both earnings and sales estimates.

Amgen (AMGN) Wins Patent Appeal for Blockbuster Psoriasis Drug

The Appeal Court's decision upholding the patents for Amgen's (AMGN) blockbuster psoriasis drug Otezla will prevent drug-makers from selling a generic version till February 2028.

Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Recurrence

Detailed data from a mid-stage study shows that Moderna (MRNA)/Merck's personalized cancer vaccine candidate reduces the risk of recurrence/death.

Indrajit Bandyopadhyay headshot

4 Medical Stocks to Buy as Rate Hike Cycle Nears End

We have narrowed our search to four U.S.-based medical stocks with attractive valuations. These are HROW, LSTA, OCUP and PRE.